Company intelligence / Profile preview

Ribozyome

Boulder, Colorado, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

The company had several products in clinical trials, including an anti-Hepatitis C virus ribozyme partnered with Eli Lilly, and Angiozyme (an anti-angiogenic ribozyme) in Phase I/II trials for cancer patients at the Cleveland Clinic. They also had Herzyme, targeting HER-2 for breast and ovarian cancer treatment, in pre-clinical studies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: RNA-based therapeuticsribozymes
Industry: Biotech

Drug pipeline

1 asset

anti-HIV-1 tat ribozyme

Partnerships

Eli LillyChiron CorporationMedizyme Pharmaceuticals (joint venture with Elan Corp affiliate)

Beyond the preview

Go deeper on Ribozyome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribozyome.

Explore the full profile